Independently verified. Pallone (D-NJ) was the author and lead sponsor of H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act, reintroduced in the 117th Congress on April 22, 2021 (91 cosponsors), which required Medicare negotiation of at least 25 single-source brand-name drugs (plus all insulin) rising to 50 -- confirmed via Wikipedia. The literal H.R. 3 bill did NOT become law (referred to committee, no further advancement). However, the promise's two operative objectives -- (1) empower Medicare to negotiate lower prescription drug prices and (2) cap out-of-pocket costs for Part D enrollees -- were both enacted and are in force via the Inflation Reduction Act of 2022, whose drug-pricing title derived from the House Energy & Commerce drug-pricing provisions that Pallone, as E&C Chairman, authored and drove, and for which he voted. KFF confirms Medicare now negotiates prices (10 Part D drugs effective Jan 1, 2026; 15 in 2027; 15+ in 2028, expanding). The $2,000 annual Part D out-of-pocket cap took effect January 1, 2025 and the $35 monthly insulin cap took effect January 2023. Applied under a nonpartisan mirror standard: the promised end-state (Medicare empowered to negotiate; Part D out-of-pocket costs capped) is realized and he demonstrably drove it, which supports FULL. Confidence held at 0.85 (not higher) because the enacted negotiation scale is materially smaller than H.R. 3's literal 25-then-50 drugs-per-year target and the named vehicle itself failed -- a genuine FULL-vs-CHAMPIONED boundary case. Source note: the prior rating's Energy & Commerce press-release URL and the congress.gov bill page both returned HTTP 403 on fetch (bot-blocking); the unverifiable E&C quote was replaced with the independently fetched KFF source.